

- **PREGNANCY** Avoid.
- **BREAST FEEDING** Avoid.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution in combined hepatic and renal impairment.  
**Dose adjustments** Manufacturer advises dose reduction in combined hepatic and renal impairment.
- **RENAL IMPAIRMENT** Avoid if eGFR less than 20 mL/minute/1.73 m<sup>2</sup>.  
**Dose adjustments** Use two-thirds of normal dose if eGFR 50–80 mL/minute/1.73 m<sup>2</sup>; use one-third of normal dose in 2 divided doses if eGFR 30–50 mL/minute/1.73 m<sup>2</sup>; use one-sixth of normal dose as a single dose if eGFR 20–30 mL/minute/1.73 m<sup>2</sup>.
- **TREATMENT CESSATION** Avoid abrupt withdrawal.
- **DIRECTIONS FOR ADMINISTRATION** Follow the oral solution with a glass of water (or soft drink) to reduce bitter taste.
- **PRESCRIBING AND DISPENSING INFORMATION** Piracetam has been used in children 16 years and over as adjunctive treatment for cortical myoclonus.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

CAUTIONARY AND ADVISORY LABELS 3

- ▶ **Nootropil** (UCB Pharma Ltd)

**Piracetam 333.3 mg per 1 mL** Nootropil 33% oral solution sugar-free | 300 mL [PoM] £16.31 DT = £16.31

**Tablet**

CAUTIONARY AND ADVISORY LABELS 3

- ▶ **Nootropil** (UCB Pharma Ltd)

**Piracetam 800 mg** Nootropil 800mg tablets | 90 tablet [PoM] £11.75 DT = £11.75

**Piracetam 1.2 gram** Nootropil 1200mg tablets | 60 tablet [PoM] £10.97 DT = £10.97

**MONOAMINE DEPLETING DRUGS****Tetrabenazine**● **INDICATIONS AND DOSE**

**Movement disorders due to Huntington's chorea, hemiballismus, senile chorea, and related neurological conditions**

- ▶ BY MOUTH

▶ **Adult:** Initially 25 mg 3 times a day, then increased, if tolerated, in steps of 25 mg every 3–4 days; maximum 200 mg per day

▶ **Elderly:** Lower initial dose may be necessary

**Moderate to severe tardive dyskinesia**

- ▶ BY MOUTH

▶ **Adult:** Initially 12.5 mg daily, dose to be gradually increased according to response

- **CONTRA-INDICATIONS** Depression · parkinsonism · phaeochromocytoma · prolactin-dependent tumours
- **CAUTIONS** Susceptibility to QT-interval prolongation
- **INTERACTIONS** → Appendix 1: tetrabenazine
- **SIDE-EFFECTS**
  - ▶ **Common or very common** Anxiety · confusion · constipation · depression · diarrhoea · drowsiness · hypotension · insomnia · nausea · parkinsonism · vomiting
  - ▶ **Uncommon** Consciousness impaired · hyperthermia
  - ▶ **Rare or very rare** Neuroleptic malignant syndrome · skeletal muscle damage
  - ▶ **Frequency not known** Bradycardia · dizziness · dry mouth · epigastric pain · suicidal ideation
- **PREGNANCY** Avoid unless essential—*toxicity in animal studies.*
- **BREAST FEEDING** Avoid.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution (increased risk of exposure), particularly in severe impairment (no information available).  
**Dose adjustments** Manufacturer advises initial dose reduction of 50% and slower dose titration in mild to moderate impairment.
- **RENAL IMPAIRMENT** Use with caution.
- **TREATMENT CESSATION** Avoid abrupt withdrawal.
- **PATIENT AND CARER ADVICE**  
**Driving and skilled tasks** May affect performance of skilled tasks (e.g. driving).

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension  
**Tablet**

CAUTIONARY AND ADVISORY LABELS 2

- ▶ **Tetrabenazine (Non-proprietary)**

**Tetrabenazine 25 mg** Tetrabenazine 25mg tablets |

112 tablet [PoM] £107.69 DT = £107.69

- ▶ **Tardiben** (AOP Orphan Pharmaceuticals AG)

**Tetrabenazine 25 mg** Tardiben 25mg tablets | 112 tablet [PoM]

£100.00 DT = £107.69

- ▶ **Xenazine** (Alliance Pharmaceuticals Ltd)

**Tetrabenazine 25 mg** Xenazine 25 tablets | 112 tablet [PoM]

£100.00 DT = £107.69

**MUSCLE RELAXANTS > PERIPHERALLY ACTING > NEUROTOXINS (BOTULINUM TOXINS)****Botulinum toxin type A**

27-Nov-2019

● **INDICATIONS AND DOSE**

**Hand and wrist disability due to upper limb spasticity associated with stroke (specialist use only) | Foot and ankle disability due to lower limb spasticity associated with stroke (specialist use only) | Blepharospasm (specialist use only) | Hemifacial spasm (specialist use only) | Spasmodic torticollis (specialist use only) | Severe hyperhidrosis of the axillae (specialist use only) | Prophylaxis of headaches in chronic migraine (specialist use only) | Temporary improvement of moderate to severe upper facial lines in adults under 65 years (specialist use only) | Management of bladder dysfunctions (specialist use only) | Chronic sialorrhoea [due to neurological disorders] (specialist use only)**

- ▶ BY SUBCUTANEOUS INJECTION, OR BY INTRADERMAL INJECTION, OR BY INTRAMUSCULAR INJECTION, OR BY LOCAL INFILTRATION

- ▶ **Adult:** (consult product literature)

**DOSE EQUIVALENCE AND CONVERSION**

- ▶ **Important:** information is specific to each individual preparation.

- **CONTRA-INDICATIONS** Acute urinary retention (specific to use in bladder disorders only) · catheterisation difficulties (specific to use in bladder disorders only) · infection at injection site · presence of bladder calculi (specific to use in bladder disorders only) · urinary tract infection (specific to use in bladder disorders only)

● **CAUTIONS**

**GENERAL CAUTIONS** Atrophy in target muscle · chronic respiratory disorder · elderly · excessive weakness in target muscle · history of aspiration · history of dysphagia · inflammation in target muscle · neurological disorders · neuromuscular disorders · off-label use (fatal adverse events reported)

**SPECIFIC CAUTIONS**

- ▶ When used for blepharospasm or hemifacial spasm Risk of angle-closure glaucoma

**CAUTIONS, FURTHER INFORMATION** Neuromuscular or neurological disorders can lead to increased sensitivity and